New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
11:07 EDTESRX, WLPExpress Scripts sell-off an overreaction, says JPMorgan
JPMorgan says shares of Express Scripts (ESRX) are trading lower after WellPoint (WLP) discussed expectations for lower enrollment in 2013. However, JPMorgan thinks lower enrollment in 2013 is already factored into current expectations for Express Scripts and views today's pullback as an overreaction.
News For ESRX;WLP From The Last 14 Days
Check below for free stories on ESRX;WLP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
09:47 EDTESRXExpress Scripts' TriCare contract renewal removes an overhang, says UBS
UBS said Express Scripts successful renewal of the TriCare/Department of Defense PBM contract removes an overhang and should contribute 25c-30c to 2014 earnings. The firm expects shares to react positively and reiterates its Buy rating and $72 price target.
09:38 EDTESRXExpress Scripts TRICARE contract removes key overhang, says Citigroup
Citigroup believes the Express Scripts retaining the Department of Defense's TRICARE Pharmacy Program contract removes a key overhang on the stock and validates the company's business model. Citi reiterates a Buy rating on Express Scripts with a $92 price target.
April 19, 2014
18:41 EDTESRXExpress Scripts awarded 7-year TRICARE Pharmacy Program contract
Subscribe for More Information
April 17, 2014
12:53 EDTWLPOn The Fly: Midday Wrap
Subscribe for More Information
10:51 EDTWLPHealth insurers slide after UnitedHealth results, cautious comments
Shares of a number of health insurers are falling after the largest company in the sector, UnitedHealth (UNH), reported slightly higher than expected first quarter profit but lower than expected revenue. WHAT'S NEW: UnitedHealth's first quarter earnings per share came in at $1.10, versus the consensus outlook of $1.09. The insurer reported revenue of $31.71B, compared with the consensus outlook of $31.99B. Taxes levied by the Affordable Care Act and weak funding of Medicare Advantage by the government weighed on UnitedHealth's earnings, the company stated. Also pushing down the company's earnings was "a very expensive," new Hepatitis C therapy, UnitedHealth stated on its earnings conference call. Hepatitis C treatments cost UnitedHealth hundreds of millions of dollars in the first quarter, the company stated, though it also noted that demand for the treatments should drop going forward as initial pent-up demand for them starts to decline. The company indicated that it was looking to be reimbursed by states for the money it is spending on hepatitis vaccines for Medicaid patients. Meanwhile, UnitedHealth reiterated its fiscal 2014 EPS guidance of $5.40-$5.60 and its fiscal 2014 revenue guidance of $128B-$129B. PRICE ACTION: In mid-morning trading, UnitedHealth sank 3.7% to $75.31. Other health insurers also declined, with WellPoint (WLP) dropping 4% to $91.89, Aetna (AET) falling 3.3% to $67.54, Humana (HUM) declining 2.25% to $106.35, and Health Net (HNT) sliding 1% to $31.74.
April 16, 2014
10:08 EDTWLPUnitedHealth retreats after Citi cuts rating on shares
Subscribe for More Information
09:01 EDTWLPWellPoint names Martin Silverstein as Chief Strategy Officer, effective April 28
WellPoint announced Martin Silverstein, M.D., has been named chief strategy officer, effective April 28. In this role, Dr. Silverstein will oversee WellPointís enterprise marketing, corporate development and strategy functions, and will be responsible for short and long-term strategic planning to ensure the company is maximizing the value of its assets and capturing growth across its geographies and businesses. Silverstein joins WellPoint from The Boston Consulting Group where he was a Senior Partner and Managing Director.
April 15, 2014
06:32 EDTWLPPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 10, 2014
15:56 EDTWLPWellCare rumored to be takeover target, Betaville blog says
Wellcare (WCG) which has previously been speculated as a takeover target by analysts, is being studied as a target by Wellpoint (WLP), according to the Betaville blog, which cites sources familiar with the matter. Shares of WellCare, which have been lower throughout the session, briefly spiked following the blog post, but have returned to negative territory in late afternoon trading. Reference Link
April 9, 2014
11:43 EDTESRXGilead defended by analysts after recent pullback
Subscribe for More Information
08:41 EDTESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use